The e-Intervention Enhancing Mental Health in Adolescents project, IMPROVA, will co-design, pilot, evaluate, and facilitate the upscaling of a modular eHealth intervention platform that aims to improve mental health and well-being, early detect mental health problems and prevent common mental disorders in adolescents. The IMPROVA consortium includes an international and inter-disciplinary group of researchers and practitioners from health, educational and social sciences in addition to computer scientists, a teacher association and policymakers. The IMPROVA online platform will be co-created with stakeholder groups, including adolescents, parents, teachers, school health professionals and policymakers based on materials already designed and tested in more than 20 projects carried out by the consortium members. The platform will include components for adolescents, parents, teachers, and school health professionals in complementary and synergistic modules. After a series of pilot testing sessions, IMPROVA will be implemented by conducting a randomized Stepped Wedge Trial Design (SWTD) in secondary education schools randomly selected in four countries (France, Germany, Romania and Spain), including 12,800 adolescents. Effectiveness, cost-effectiveness and cost-benefit will be calculated. Using implementation science methodology, IMPROVA will co-design with policymakers and stakeholders transferable evidence-based practices, methodologies and guidance for upscaling of the IMPROVA platform. IMPROVA aims to provide stakeholders and policy makers with an evidence-based, innovative, large-scale, comprehensive intervention, and a scale-up plan to promote mental health and prevent mental disorders in adolescents; empower adolescents and families to make better decisions regarding their mental health; and provide schools and the community with tools to achieve a society with better mental health and lower stigma.

Share4Rare is a collective awareness platform of patients, caregivers, researchers and other stakeholders involved in the Healthcare of Rare Diseases (RD). Based on a socially innovative approach, and building on citizen science and collective intelligence, we will engage and connect all the relevant stakeholders, towards the improvement of the quality of life, the management and the collection of scientific knowledge. The platform will be built around three important pillars: care, education and research. Our Collective Awareness Platform will take advantage of the high-motivated group of citizens (from patients to researchers, from volunteers to public health representatives and health professionals) linked or not to rare diseases, and their expertise. It will build on existing knowledge and initiatives, and will ensure a space for debate and co-creation, and a space for further research. S4R will be based on the shared open data, and on the priorities set collectively. Collective intelligence from patients and families, democratic and transparent participation and a secure environment focused on three layers of interaction will ensure a platform to put in value citizen science that is needed to promote new research initiatives with a patient centred approach.

Cancer has become an important public health problem worldwide and inequalities in access to malignancies control result in differences in patients’ outcome. Despite the recent improvement of survival rates in childhood leukaemia, there is still a gap in survival between regions, even within well-organized international cooperative groups. Childhood leukaemia care should be addressed from a global point of view, considering not only scientific aspects, the amount of technological and human resources and the current health policies, but also economic, cultural, social, educational and environmental particularities across countries. The aim of CLOSER is to harmonize the levels of care and reduce inequalities in the outcome of childhood leukaemia patients in the Community of Latin American and Caribbean States (CELAC), and in European countries. To do that, we will create a framework of collaborative, multidisciplinary research between CELAC and European regions. From a scientific point of view, we seek to boost a constant exchange of the knowledge on the biology and the technological approaches needed for the diagnosis and follow-up of childhood leukaemia between regions, provide additional resources to perform research and develop new simplified methods to assure a fast translation from bench to bedside. From a social and educative point of view, we will empower patients and families in leukaemia care and encourage the participation of civil society by analysing their particular needs, by promoting advocacy tools, launching a platform to exchange initiatives and experiences in patients care, always acting with the highest respect for the individualities of each country and with the objective to contribute to a better quality of life. To make sure that we approach childhood leukaemia care from an integral perspective, we will include as partners researchers, physicians, patients and families, patients’ organizations, policymakers, small and medium-sized enterprises and civil society representatives. CLOSER will allow a more fluent collaboration worldwide to improve childhood leukaemia control and the quality of life of the patients and their caregivers.

Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable bowel syndrome (IBS), with over 60 million Europeans affected, mostly women, by devastating manifestations, impaired treatment and quality of life. Estimated costs are €43 billion/year for IBS, mostly derived from comorbid IBS. Our hypothesis is that comorbid IBS represents a distinct clinical entity, arising from distorted brain-gut communication with a unique, specific, but undefined pathophysiological origin, differing from IBS alone. DISCOvERIE was created to advance the understanding of its causative mechanisms. Identification, validation and comprehension of these mechanisms will help stratify these patients into distinct clinical phenotypes, improving disease management, increasing quality of life and reducing socioeconomic costs. In particular, we will deliver specific comorbid-IBS physiopathological knowledge as clinical guides and protocols for newly created, hospital-based, transversal and multidisciplinary units for implementing personalized management and wellbeing of European citizens and to position Europe as a global leader in comorbid IBS personalised medicine. We will also deliver prognostic and therapeutic biomarkers and patents, technological innovation via e-health tools for personalized assessment of clinical/nutritional/physical activity and disseminate new knowledge widely. Impact will be assessed by recording media presence, scientific publications and by monitoring health-related quality of life of patients and promoting cost-effective care. To this end we have created a user board involving patient associations, clinical specialists, European healthcare experts, large pharma and SMEs representatives. We will also promote the creation of a European Reference Network for comorbid IBS involving healthcare providers across Europe.